CTOR — CITIUS ONCOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1851484 ·
Last close
$0.66
Market Cap
$61.74M
52W High
$1.00
52W Low
$0.49
ADV30
87,753
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,667,298 | 1,338,420 | -28,613,595 | -26,609,695 | 100,699,168 | 2,632,634 | 65,430,399 |
| Dec 2025 | 3,944,111 | 3,154,903 | -4,678,838 | -5,534,069 | 109,973,406 | 7,295,451 | 51,559,705 |
| Sep 2025 | 0 | — | -4,711,512 | -4,996,656 | 100,942,881 | 3,924,908 | 56,076,650 |
| Jun 2025 | 0 | — | -4,944,961 | -5,369,956 | 91,709,079 | 112 | 59,311,166 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,678,610
Investing CF
$-5,000,000
Financing CF
$14,894,290
CapEx
$-5,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.52
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,183,720
Inventory
$22,659,590
Receivables
$1,079,055
ST Investments
—
EBIT TTM
$-41,651,962
Pretax Income TTM
$-41,948,866
Interest Exp TTM
$296,904
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,611,409
EBITDA
—
Free Cash Flow
$-23,616,774
Enterprise Value
$62,906,996
Total Cash
$2,632,634
Total Debt
$3,800,111
Shares Out
92,981,204
Trailing EPS
$-0.48
Book Value
$0.38
ROE
-119.9%
ROA
-28.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -23,522,750 | -24,761,369 | 100,942,881 | 56,076,650 | — | -5,492,046 |
| Sep 2024 | 0 | -20,572,747 | -21,148,747 | 84,368,878 | 38,228,539 | — | 126,353 |
| Sep 2023 | 0 | -12,121,241 | -12,697,241 | 47,734,895 | 22,199,235 | — | 0 |
| Sep 2022 | 0 | -4,856,599 | -5,432,599 | 42,690,182 | 6,422,781 | — | 0 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MNOV | MEDICINOVA INC | $60.54M | $1.23 | — |
| IBO | IMPACT BIOMEDICAL INC. | $63.08M | $0.58 | — |
| FLNA | FILANA THERAPEUTICS, INC. | $60.38M | $1.25 | — |
| ACRV | Acrivon Therapeutics, Inc. | $63.35M | $1.48 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $59.20M | $1.11 | — |
News headlines (Yahoo Finance, 1h cache)
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
2026-06-01 11:00 · Yahoo
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
2026-05-26 12:00 · Yahoo
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
2026-05-24 11:49 · Yahoo
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
2026-05-15 20:30 · Yahoo
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
2026-05-15 20:30 · Yahoo
Citius raises $36.5m for Lymphir commercialisation
2026-05-06 13:04 · Yahoo
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
2026-05-06 00:00 · Yahoo
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
2026-04-29 12:00 · Yahoo
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)
2026-04-15 10:35 · Yahoo
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
2026-03-31 13:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.